|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||20.790 - 21.000|
|52 Week Range||20.400 - 31.290|
|PE Ratio (TTM)||18.43|
|Forward Dividend & Yield||0.80 (3.42%)|
|1y Target Est||N/A|
Takeda Pharmaceutical hopes that their $62 billion deal to purchase Shire will make them a global bio-pharmaceutical leader. But as Silvia Antonioli reports, it comes with a heavy debt burden.
May.08 -- Bloomberg's Eric Pfanner discusses what Takeda will look like after buying Shire on "Bloomberg Markets: European Close."
Roche jumped early Monday on unsurprisingly strong data for its hemophilia treatment, Hemlibra — prodding shares of Shire to slip.
will strengthen the Japanese group’s focus on innovative medicines and make it more “resilient” to pricing pressures in the US, its chief executive has said. , Mr Weber said, had been designed “in a way” that meant the combined company “would be very resilient and prepared for an environment which will become tougher”. In 2017, the US accounted for 66 per cent of Shire’s $15bn sales.
Exelixis (EXEL) is focused on the label expansion and life cycle management of the cabozantinib franchise in collaboration with Bristol-Myers Squibb (BMY) and Roche Holdings (RHHBY). The above diagram shows the rationale for studying cabozantinib in combination with immunotherapy in multiple cancer indications. Exelixis is currently evaluating the safety and preliminary activity, in terms of objective response rate and progression-free survival, of a combination of cabozantinib with nivolumab and a combination of cabozantinib with nivolumab and ipilimumab in advanced hepatocellular carcinoma (or HCC) indications in an ongoing Phase 2 trial.
For Christophe Weber, the boss of Japan's Takeda Pharmaceutical , securing a $62 billion (46 billion pound) deal last week to buy drugmaker Shire (SHP.L) at the fifth time of asking was the easy bit. At the same time he must win shareholders' support for the largest-ever overseas purchase by a Japanese company - something he told Reuters could be helped by bringing in one or more long-term, large strategic investor.
For Christophe Weber, the boss of Japan's Takeda Pharmaceutical , securing a $62 billion deal last week to buy drugmaker Shire (SHP.L) at the fifth time of asking was the easy bit. At the same time he must win shareholders' support for the largest-ever overseas purchase by a Japanese company - something he told Reuters could be helped by bringing in one or more long-term, large strategic investor.
This is pharma now, says Takeda Pharmaceutical Co. Chief Executive Officer Christophe Weber, and the outlook isn’t any better. Scale up, says the French executive who’s run Takeda since 2015 and is currently in London seeking investor support for its planned $62 billion takeover of Shire, whose gastroenterology, neuroscience and rare-disease businesses he says are critical to accelerating the company’s transformation. Just a week ago Takeda clinched a deal to take over Shire, a company that’s about 50 percent bigger than its Osaka-based buyer by market value.
After topping the $110 level in March 2018, shares of Nektar Therapeutics (NASDAQ:NKTR) are in a downtrend. It is worth noting that even though Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Endo International PLC (NASDAQ:ENDP) are starting to attract investors, NKTR stock is more attractive because of the drug’s inherent properties. Nektar collaborated with Bristol-Myers Squibb Company (NYSE:BMY) to develop NKTR-214 in clinical trials.
Japan's Takeda Pharmaceutical Co Ltd on Monday forecast a 17 percent drop in operating profit for the year through March 2019 as blood cancer drug Velcade looks set to face generic competition in the United States. The loss of Velcade's exclusivity will be partly offset by growing sales of bowel disease treatment Entyvio and heartburn and ulcer drug Takecab, but Takeda's lower overall profitability underscores the firm's need to bolster its drug pipeline. "It's always hard in a pharmaceutical company to synchronise your pipeline with your generic exposure," Takeda Chief Executive Christophe Weber said.
Takeda Pharmaceutical's £46bn (US$62bn) acquisition of London-listed rare-disease specialist Shire has prompted Japan’s top drugmaker to line up a US$30.85bn bridge loan, the largest raised in Asia to date. The jumbo financing is expected to provide opportunities for asset-hungry lenders, both domestic and international, to lend to Takeda either through syndication of the bridge or a refinancing planned within a year. JP Morgan is underwriting 50% of the financing, and MUFG and Sumitomo Mitsui Banking Corp are committing equally to the remainder.
Eli Lilly & Co. sees your $62 billion megadeal and raises you a … $1.6 billion purchase of a tiny cancer-drug developer. Two days after Takeda Pharmaceutical Co. Ltd. announced its seismic acquisition of Shire PLC, Lilly came along with a more modest, and arguably smarter, takeover of ARMO BioSciences Inc. It’s a contrast in M&A philosophies, and the market reaction so far has also been divergent: Lilly’s shares rose about 2 percent after the Thursday morning announcement, while Takeda’s have taken a beating since rumors of its Shire pursuit emerged.
Takeda Pharmaceutical Co.’s ambitions for expansion in the lucrative U.S. health-care market led the Japanese drugmaker to begin a painstaking examination of Shire Plc’s assets more than two years prior to striking a $62 billion deal. In particular, Shire’s neuroscience unit and its gastrointestinal products sparked Takeda’s interest. Shire’s struggling stock performance after its failed sale to AbbVie Inc. and the acquisition spree that followed, culminating with the $32 billion takeover of Baxalta Inc., frustrated investors and prompted concerns about its strategy.
Takeda Pharmaceutical Co. investors may belatedly be coming around to the view that the $62 billion purchase of Shire Plc is the best thing that could have happened to the Japanese drugmaker. To get the same U.S. exposure, and generate cost savings, Takeda might have looked to Celgene Corp. or Biogen Inc., according to Datamonitor Healthcare analyst Edward Thomason. Tack on the 65 percent premium Takeda offered Shire shareholders and you’re talking an awful lot of money.
Moody's Investors Service ("Moody's") placed the ratings of Shire plc ("Shire") and subsidiaries under review for upgrade. This rating action follows the announcement that Shire's board recommends that shareholders vote in favor of Takeda Pharmaceutical Company Limited's offer to acquire Shire for approximately JPY6.7 trillion (USD62 billion). Takeda's rating is A2 under review for possible downgrade, and the rating review of Shire will be tied to the ongoing rating review of Takeda.
Takeda Pharmaceutical Co.’s credit rating was downgraded by Moody’s Investors Service one day after the Japanese drugmaker said it had reached a deal to buy larger rival Shire Plc for about $62 billion. Takeda’s debt rating was cut to A2 from A1 on Wednesday, bringing it down one notch to the sixth-highest investment-grade level. Chief Executive Officer Christophe Weber capped a drawn-out pursuit of the U.K.-listed company on Tuesday, announcing an acquisition that will give Takeda wider reach into the U.S., the world’s biggest drug market, and strengthen its global pipeline.
Moody's Japan K.K. has downgraded to A2 from A1 the issuer and senior unsecured ratings of Takeda Pharmaceutical Company Limited. Moody's has also placed Takeda's A2 issuer and senior unsecured ratings under review for further downgrade following Takeda's announcement on 8 May 2018 that it will acquire all of the outstanding shares in Shire plc (Baa3 positive) for approximately JPY7 trillion (USD64 billion). Prior to the Shire announcement, Takeda's rating outlook had been negative due to elevated leverage after a previous major acquisition last year.
Takeda Pharmaceutical Co.’s Chief Executive Officer Christophe Weber navigated rebuffs, critics and a plunging stock price to win a $62 billion deal to acquire larger rival Shire Plc. Integrating the Japanese drugmaker -- which began by selling herbal therapies 237 years ago -- with the sprawling American company will be even more complicated. As the Osaka-based company’s first foreign head, Weber is overseeing a dramatic makeover that will reshape Takeda into a global powerhouse with a plum suite of drugs for rare diseases.
Takeda Pharmaceutical Co. on Tuesday reached an agreement to buy Shire PLC, capping a monthslong battle for control of the European drugmaker and marking the biggest-ever overseas acquisition by a Japanese company. Shire’s board agreed Takeda could buy it at £49.01 or $66.21 a share—$30.33 in cash and 0.839 of a Takeda share for each Shire share—in a deal that valued the target at $62 billion. The acquisition would create the world’s eighth-largest drugmaker with combined sales worth $30 billion, and bolsters Takeda Chief Executive Christophe Weber’s mission to gain a greater foothold in more lucrative markets such as the U.S. and Europe.
Stocks finished mixed on Tuesday after President Trump announced that the U.S. would withdraw from the Iran nuclear deal.
Takeda Pharmaceutical Co Ltd. agreed Tuesday to purchase rare-disease drugmaker Shire Plc for $62 billion. But this blockbuster deal comes with blockbuster risk. Takeda will be paying a steep premium and taking on big debt to acquire a company with uncertain prospects. Shire’s hemophilia business provides more than a quarter of its revenue.
with Shire are higher than the market currently thinks. The cash and stock deal will solve a major strategic problem for Takeda since drug sales in Japan are falling due to an aging population and fairly strict government regulations on drug prices. Shire books a majority of its sales in the U.S., where the long term industry outlook is brighter and pricing is more permissive.
Bloomberg's Eric Pfanner discusses what Takeda will look like after buying Shire on "Bloomberg Markets: European Close." (Source: Bloomberg)